Joined June 2022
- Tweets 66
- Following 32
- Followers 221
- Likes 28
31 Photos and videos
$CLDI's CEO Eric Poma joined the @NanoCapPod to discuss Calidi's oncolytic virus platform, its potential to transform cancer treatment, and the Company's clinical strategy.
Listen:
@Spotify: bit.ly/4e5Eghb
@ApplePodcasts: apple.co/4an9PSD
3
2
8
248
$CLDI's CEO, Dr. Eric Poma, will participate in an investor webinar hosted by @RedChip on June 9, at 1:15pm PT. Dr. Poma will share an in-depth overview of Calidi's breakthrough RedTail platform & highlight the progress of its lead candidate, CLD-401.
🔗 bit.ly/4ebn9uE
2
8
254
June is #NationalCancerSurvivorMonth, a time to honor the strength and resilience of cancer survivors, caregivers, and families impacted by cancer.
Their journeys continue to inspire advances in targeted immunotherapies for difficult-to-treat cancers.
$CLDI
1
2
10
205
Dr. Eric Poma has served as $CLDI's CEO and Director since April 2025.
Dr. Poma brings over three decades of experience in the biopharmaceutical industry, including clinical program development, big pharma collaboration agreements, and a strong record of capital fundraising.
10
2,817
Last week’s earnings release highlighted recent milestones across $CLDI's RedTail platform and pipeline programs, including new @AACR and @ASGCTherapy presentations and continued advancement of CLD-401.
Get the full Q1 update here: bit.ly/4uYDXvF
1
8
173
$CLDI announces that two abstracts showcasing its RedTail platform have been accepted for online publication at @ASCO 2026. The company will present preclinical data on its lead program, CLD-401.
Full press release here: bit.ly/42SoZeC
#ASCO26
9
94
This #ClinicalTrialsDay, $CLDI recognizes the patients, investigators, clinicians, & researchers advancing clinical research. The Calidi team is focused on engineering the future of genetic medicine through our proprietary platforms.
More on our pipeline: bit.ly/4dymfrs
9
78
$CLDI reports its first quarter 2026 operating and financial results and reviews recent business highlights.
Full press release here: bit.ly/4uYDXvF
8
110
$CLDI's CSO and Head of Technical Operations, Dr. Antonio F. Santidrian, will detail the exciting promise of our RedTail platform and present new data on its first lead, CLD-401, at the annual @ASGCTherapy conference
Full press release here: bit.ly/4uQbjg9
#ASGCT2026
9
79
$CLDI's RedTail platform is genetically engineered to avoid immune clearance, enabling systemic administration. Since replication only occurs in tumor cells, the delivery of genetic medicines is precisely targeted to the tumor.
Learn about RedTail’s MOA: bit.ly/4d89lR5
9
73
$CLDI is engineering the future of genetic medicine, delivering therapies precisely to sites of disease to advance oncology and other indications.
Learn more about our unique approach to precisely delivering genetic medicines to sites of disease: calidibio.com
1
11
88
2 Sep 2025
📣 We are excited to announce that CEO, Dr. Eric Poma, will be presenting at the H.C. Wainwright 27th Annual Global Investment Conference, taking place September 8–10, 2025 at the Lotte New York Palace Hotel in NYC.
Read more here: globenewswire.com/news-relea…
#calidi #redtail $CLDI
4
3
7
984
30 Jul 2025
We are thrilled to announce that CLD‑201 (SuperNova), our allogeneic adipose stem-cell loaded oncolytic virus, has received FDA Fast Track designation for the treatment of patients with soft tissue sarcoma.
Read more here: calidibio.com/calidi-biother…
#CLD201 #calidi #FastTrack
6
5
17
1,170
30 Jun 2025
We are excited to announce a shareholder letter from CEO, Eric Poma, PhD, highlighting changes in Calidi's leadership, its focus and priorities, and in its balance sheet and operating expenses.
Read more here: calidibio.com/calidi-biother…
#calidi #redtail #virotherapy $CLDI
1
4
12
1,844
24 Jun 2025
Calidi Biotherapeutics CEO, Eric Poma, represented the company at the BIO conference in Boston last week! Dr. Poma had a series of productive meetings that highlighted Calidi’s innovative approach and deep commitment to advancing immuno-oncology.
#calidi #virotherapy #BIO $CLDI
2
3
13
2,719
2 Jun 2025
@CalidiBio today announced the presentation of its lead RedTail platform candidate, CLD-401, at the American Society of Clinical Oncology @ASCO Annual Meeting.
Read more here: calidibio.com/calidi-biother…
#calidi #redtail #systemic #asco $CLDI
4
2
10
1,635
15 May 2025
📣 Calidi Biotherapeutics Reports First Quarter 2025 Financial Results and Recent Operational Highlights
Read more to learn about Calidi's recent corporate developments: ir.calidibio.com/news/news-d…
#calidi #redtail #virotherapy $CLDI
2
3
801
23 Apr 2025
@CalidiBio today announced the succession of its CEO, Allan Camaisa, to Eric Poma, Ph.D., who was appointed as CEO and member of the Board of Directors of Calidi. Mr. Camaisa will continue to serve as a member of the Board.
Read more here: calidibio.com/newsroom/post/…
1
3
416
10 Apr 2025
We are thrilled to announce the appointment of Travis Clifton, MD as Chief Medical Officer, Consultant and Advisor.
Read more here: calidibio.com/newsroom/post/…
4
352
31 Mar 2025
@CalidiBio is pleased to report fourth quarter and full-year 2024 financial results and recent operational highlights. These include:
Read more about these exciting updates here: calidibio.com/newsroom/post/…
4
298